• The Barrow Neuroplex
  • Find a Doctor
  • International Patients
  • Contact Us
  • Patients & Families
  • Education
  • Research
  • Departments & People
  • News & Stories
  • Transfer a Patient
  • SAS


    Enrollment Information

    Call (602) 406-1466 or E-Mail [email protected]

    This is a longitudinal, observational study of ambulatory and non-ambulatory adult patients with genetically confirmed chromosome 5q spinal muscular atrophy (SMA) to examine the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) for up to 30 months.

    This study does not provide SPINRAZA or cover costs associated with standard clinical care. These patients will be treated by their respective physicians according to standard clinical practice. Study visits include standardized assessments of strength and function, and occur at baseline, day 15, after treatment initiation, day 30, day 60, and then at 4-month intervals through month 30.

    Principal Investigator: Shafeeq Ladha, MD

    About Barrow Neurological Institute
    Since our doors opened as a regional specialty center in 1962, we have grown into one of the premier destinations in the world for neurology and neurosurgery. Our experienced, highly skilled, and comprehensive team of neurological specialists can provide you with a complete spectrum of care–from diagnosis through outpatient neurorehabilitation–under one roof. Barrow Neurological Institute: Discover. Educate. Heal.